Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 681-699 , December 2007

Thalidomide in the treatment of multiple myeloma

References 

  1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine. 1999;341(21):1565–1571
  2. Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clinical Pharmacokinetics. 2004;43(5):311–327
  3. Eriksson T, Hoglund P, Turesson I, et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. The Journal of Pharmacy and Pharmacology. 2003;55(12):1701–1706
  4. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochemical Pharmacology. 1998;55(11):1827–1834
  5. Teo SK, Scheffler MR, Kook KA, et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharmaceutics & Drug Disposition. 2000;21(1):33–40
  6. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. European Journal of Clinical Pharmacology. 2001;57(5):365–376
  7. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. The Journal of Experimental Medicine. 1991;173(3):699–703
  8. Rowland TL, McHugh SM, Deighton J, et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology. 1998;40(1):11–20
  9. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. The Journal of Experimental Medicine. 1993;177(6):1675–1680
  10. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology. 1999;163(1):380–386
  11. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. The Journal of Biological Chemistry. 2001;276(25):22382–22387
  12. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. The Journal of Experimental Medicine. 1998;187(11):1885–1892
  13. Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrobial Agents and Chemotherapy. 2000;44(9):2286–2290
  14. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–216
  15. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31(2–3):213–221
  16. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(9):4082–4085
  17. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer. 2002;87(10):1166–1172
  18. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15(12):1950–1961
  19. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. Journal of Clinical Oncology. 2005;23(23):5334–5346
  20. Payvandi F, Wu L, Haley M, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology. 2004;230(2):81–88
  21. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8):3286–3294
  22. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943–2950
  23. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochemical Pharmacology. 2000;59(12):1489–1499
  24. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525–4530
  25. Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. American Journal of Medicine. 2002;112(5):412–413
  26. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. American Journal of Medicine. 2004;117(7):508–515
  27. Hall VC, El-Azhary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. Journal of the American Academy of Dermatology. 2003;48(4):548–552
  28. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology. 2002;20(21):4319–4323
  29. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. The New England Journal of Medicine. 2000;343(13):972–973
  30. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98(2):492–494
  31. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology. 2001;12(7):991–995
  32. Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86(4):399–403
  33. Alexanian R, Weber D, Anagnostopoulos A, et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology. 2003;40(4 Suppl. 4):3–7
  34. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4):856–863
  35. Dimopoulos MA, Hamilos G, Zomas A, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. The Hematology Journal. 2004;5(2):112–117
  36. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168–1171
  37. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 2006;24(3):431–436
  38. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825–831
  39. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614–1615
  40. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2006;354(10):1021–1030
  41. Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clinical Lymphoma. 2003;4(1):32–35
  42. Zangari M, Saghafifar F, Mehta P, et al. The blood coagulation mechanism in multiple myeloma. Seminars in Thrombosis and Hemostasis. 2003;29(3):275–282
  43. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. British Journal of Haematology. 2006;134(4):399–405
  44. Streetly M, Hunt BJ, Parmar K, et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. European Journal of Haematology. 2005;74(4):293–296
  45. Ward CM, Yen T, Harvie R, et al. Elevated levels of factor VIII and von Willebrand Factor after thalidomide treatment for malignancy: relationship to thromboembolic events. The Hematology Journal. 2003;4:S251;[abstract 365; suppl]
  46. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology. 2004;126(5):715–721
  47. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology. 2003;21(1):16–19
  48. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004;18(12):2044–2046
  49. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proceedings. 2005;80(12):1568–1574
  50. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients–report of the Intergroupe Francophone du Myelome (IFM). The Hematology Journal. 2002;3(4):185–192
  51. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clinical Cancer Research. 2002;8(11):3377–3382
  52. Schey SA, Cavenagh J, Johnson R, et al. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research. 2003;27(10):909–914
  53. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology. 2005;74(3):212–216
  54. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology. 2002;59(12):1872–1875
  55. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Journal of Clinical Oncology. 2006;24(27):4507–4514
  56. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology. 2004;62(12):2291–2293
  57. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica. 2001;86(4):404–408
  58. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica. 2002;87(4):408–414
  59. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 2003;102(1):69–77
  60. Waage A, Gimsing P, Juliusson G, et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology. 2004;125(2):149–155
  61. Hus I, Dmoszynska A, Manko J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer. 2004;91(11):1873–1879
  62. Grosbois B, Bellisant E, Moreau P, et al. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. [abstract 689] Blood. 2001;98:
  63. Yakoub-Agha I, Doyen C, Hulin C, et al. A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study. [Meeting Abstracts] Journal of Clinical Oncology. 2006;24(18 Suppl):7520
  64. Weber D, Delasalle K, Giralt S, et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood. 1999;94:604a
  65. Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology. 2003;121(5):768–771
  66. Palumbo A, Falco P, Ambrosini MT, et al. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. European Journal of Haematology. 2005;75(5):391–395
  67. Fermand J-P, Jaccard A, Macro M, et al. A randomized comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). ASH Annual Meeting Abstracts 2006;108(11):3563.
  68. Glasmacher A, Hahn C, Hoffmann F, et al. Thalidomide in relapsed or refractory patients with multiple myeloma: monotherapy or combination therapy? A report from systematic reviews. ASH Annual Meeting Abstracts 2005;106(11):5125.
  69. Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98(13):3846–3848
  70. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology. 2003;21(14):2732–2739
  71. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology. 2003;122(4):607–616
  72. Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91(1):133–136
  73. Kyriakou C, Thomson K, D'Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology. 2005;129(6):763–770
  74. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine. 2003;348(26):2609–2617
  75. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory Multiple Myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: Superior outcome in patients with normal cytogenetics and no prior T. ASH Annual Meeting Abstracts 2005;106(11):2552.
  76. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood. 2006;
  77. Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (vmdt) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. ASH Annual Meeting Abstracts 2005;106(11):363.
  78. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17(4):775–779
  79. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89(7):826–831
  80. Abdelkefi A, Torjman L, Ben Romdhane N, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplantation. 2005;36(3):193–198
  81. Rajkumar SV, Hussein M, Catalano J, et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts 2006;108(11):795.
  82. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35–39
  83. Macro M, Divine M, Uzunhan Y, et al. Dexamethasone + Thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. ASH Annual Meeting Abstracts 2006;108(11):57.
  84. Goldschmidt H, Sonneveld P, Breitkreuz I, et al. HOVON 50/GMMG-HD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. ASH Annual Meeting Abstracts 2005;106(11):424.
  85. Zervas K, Mihou D, Katodritou I, et al. VAD-doxil vs.VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of the Greek Myeloma Study Group. ASH Annual Meeting Abstracts 2006;108(11):794.
  86. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104(7):1428–1433
  87. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. [Meeting Abstracts] Journal of Clinical Oncology. 2006;24(18 Suppl):1
  88. Hulin C, Virion J, Leleu X, et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. [Meeting Abstracts] Journal of Clinical Oncology. 2007;25(18 Suppl):8001
  89. Dimopoulos MA, Anagnostopoulos A, Terpos E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica. 2006;91(2):252–254
  90. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108(7):2159–2164
  91. Hicks L, Haynes A, Reece DE, et al. A systematic review and meta-analysis of thalidomide in patients with previously untreated multiple myeloma. ASH Annual Meeting Abstracts 2006;108(11):3570.
  92. Alexanian R, Weber D, Giralt S, et al. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Annals of Oncology. 2002;13(7):1116–1119
  93. Stewart AK, Chen CI, Howson-Jan K, et al. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clinical Cancer Research. 2004;10(24):8170–8176
  94. Feyler S, Rawstron A, Jackson G, et al. Thalidomide maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum Phase 2 Study. ASH Annual Meeting Abstracts 2005;106(11):641.
  95. Hussein MA, Jakubowiak AJ, Bolejack V, et al. S0204: Melphalan (MEL)-Based Tandem Autotransplants (TAT) for Multiple Myeloma (MM) with Thalidomide/Dexamethasone (TD) Induction and Thalidomide/Prednisone (TP) maintenance: a Phase II Trial of the Southwest Oncology Group. ASH Annual Meeting Abstracts 2006;108(11):3088.
  96. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–3294
  97. Spencer A, Prince M, Roberts AW, et al. First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following Autologous Stem Cell Transplantation (ASCT) for patients with Multiple Myeloma (ALLG MM6). ASH Annual Meeting Abstracts 2006;108(11):58.
  98. Abdelkefi A, Ladeb S, Ben Othman T, et al. Timing of second autologous transplantations in multiple myeloma: results of a multicenter sequential randomized clinical trial. ASH Annual Meeting Abstracts 2006;108(11):59.

PII: S1521-6926(07)00067-9

doi: 10.1016/j.beha.2007.09.001

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 681-699 , December 2007

Article Tools